Downloadable, data-grounded research from the ABI Analytics desk – biosimilar and patent-cliff landscapes, sector deep-dives and the live market trackers our clients rely on. Built on primary FDA and market data.
Full PDF reports, free with your details. New therapeutic-area editions are published regularly – or request a bespoke one for your molecules and markets.
Biosimilars | Pharma
Which blockbuster cancer biologics lose exclusivity, when biosimilars enter, and what the 2028 Keytruda cliff means for developers, payers and investors.
Biosimilars | Pharma
Adalimumab, ustekinumab and the TNF and IL franchises facing exclusivity loss and biosimilar entry.
Biosimilars | Pharma
Insulins, GLP-1s and the next wave of metabolic biologics approaching exclusivity loss.
Biosimilars | Pharma
Aflibercept, ranibizumab and the retinal biologics franchise.
Any therapeutic area
Your target molecules, markets, timelines and competitive set – scoped and delivered by the ABI research desk.
Beyond one-off reports, our live dashboards track markets and events in real time.
Dashboard
Monthly macro-economic review across growth, inflation, external and fiscal indicators.
Dashboard
Tracking new listings, deal activity and acquisition targets.
Coverage
On-demand market research across 366 industries and sectors.
Tell us what you're trying to figure out. Our research desk scopes bespoke reports and advisory engagements across pharma, finance and technology.
Talk to our research desk →